The Asian Scientist 100
Can Li
Institution
University of Hong Kong
Country
Hong Kong
Field
Engineering
Li is a recipient of the 2023 Croucher Tak Wah Mak Innovation Award for his research exploring the limitations of digital computers in performing tasks accomplished by the human brain, including recognising faces, reasoning based on vague information, and learning from experience.
(Photo: University of Hong Kong)
AWARDS
- 2023 Croucher Tak Wah Mak Innovation Award
Related articles
Dr. Alex Matter Awarded 2013 Szent-Györgyi Prize For Progress In Cancer Research
Dr. Alex Matter, father of targeted cancer therapies, will receive the 8th Szent-Györgyi Prize for Progress in Cancer Research this Friday in Washington, DC.
Chinese Investment: A New Form Of Colonialism?
Yao Yang of Peking University writes that China needs to improve its international image as it expands its resource-acquisition activities across the world.
‘Third’ World Science No More
The renaming of TWAS reflects changes in development. But it must ensure that its original priorities are maintained, says David Dickson.
High Protein Diet May Help Weight Loss, Study
Australian National University researchers have found that a diet high in protein may help you lose weight.
Mosquitoes And Flies Share Close Evolutionary History
A collaborative study by an international consortium of 27 scientists has shown that the mosquito branched off the same evolutionary tree as flies 220 million years ago.
Taiwanese Doctors Show Gene Screening Prevents Drug Reactions
Taiwanese researchers have used genetic screening to prevent two potentially fatal drug-induced syndromes.
Scientists Discover Heaviest Antimatter Ever
Scientists at the Relativistic Heavy Ion Collider (RHIC) have discovered the anti-matter partner of the helium nucleus: antihelium-4.
Scientist Discover Novel Mutations That Cause Inherited Childhood Blindness
A Chinese-led team has identified novel gene mutations linked to Leber congenital amaurosis, one of the most common causes of inherited blindness in children.
First Singapore Developed Cancer Drug In Phase I Trials
SB939, a cancer drug developed in Singapore, has shown encouraging results in Phase 1 trials, and will now be tested in patients with advanced lung cancer.